

CircABCB10 promotes the proliferation and migration of lung cancer cells through down-regulating microRNA-217 expression

T.-Y. HU, Q.-X. ZHU, Q.-Y. DUAN, X.-Y. JIN, R. WU

Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China

Abstract. – OBJECTIVE: We aimed at studying the role and molecular mechanism of circular RNA circABCB10 in the progression of lung cancer (LCa).

PATIENTS AND METHODS: We collected LCa tissues using quantitative real-time polymerase chain reaction (qRT-PCR) technology to determine circABCB10 expression and performed survival analysis based on the clinical data of LCa patients. At the same time, the specific effects of circABCB10 on the biological function of LCa cell lines were determined by certain cell function experiments, including cell counting kit-8 (CCK-8) test, plate cloning experiment, transwell and cell wound healing assays. The downstream key gene microRNA-217 of circABCB10 was predicted through bioinformatics analysis and the potential regulation between them was confirmed by luciferase assay. microRNA-217 was knocked down in LCa cell lines to verify its important role in the progression of LCa.

RESULTS: CircABCB10 showed abnormally high expression in LCa tissues and cell lines and was related to the poor prognosis of patients. In vitro cell experiments demonstrated that knocking down circABCB10 remarkably suppressed the proliferation and migration ability of LCa cells. In addition, circABCB10 can specifically bind to microRNA-217 and negatively regulate its expression of microRNA-217 in LCa cells. Finally, cell functional experiments showed that microRNA-217 is a key downstream gene that mediates the regulation of circABCB10 on LCa cell function.

CONCLUSIONS: CircABCB10, abnormally highly expressed in LCa tissues, is able to induce the malignant progression of this cancer.

Key Words:

CircABCB10, Lung cancer, MicroRNA-217, Cell proliferation, Cell migration.

non-small cell lung cancer (NSCLC) is the most common one, accounting for about 80% of all cases¹. At present, LCa has become the most common cause of cancer-related deaths worldwide, with approximately 1.8 million new cases and 1.59 million deaths each year². The changes of many tumor suppressor genes and oncogenes are involved in the incidence of LCa, but the molecular and genetic basis of LCa still remains unclear³⁻⁵. Despite the emergence of new adjuvant chemotherapy regimens and targeted biologics, the prognosis of NSCLC patients is still unsatisfactory, with a low 5-year survival rate and a high recurrence rate. There is no doubt that a better understanding of its pathologic mechanisms will contribute to the development of new LCa therapy strategies.

CircRNAs (circRNAs) were originally referred to as a splicing error, which is a non-coding RNA that does not have the function of translating proteins^{6,7}. Their covalent closed-loop structure is shorter than the linear 3' and 5' terminal structure⁸. CircRNAs have been reported to affect tumor-related cellular activities, such as cell proliferation, invasion, and epithelial-mesenchymal transformation (EMT) processes^{9,10}. CircRNAs play an essential part in the regulation of tumorigenesis through interaction with tumor-related microRNAs. CircRNAs can be used as regulators of microRNA sponges, splicing and transcription, and modifiers of parental gene expression¹¹. Hsa_circ_001653 was found to be engaged in the progression of pancreatic cholangiocarcinoma through microRNA-377 /HOXC6 axis¹². CircGNB1 accelerated the progress of triple negative breast cancer through the downstream microRNA-141-5p /IGF1R signal axis¹³. In gliomas, circPITX1 inhibits the glucose metabolism pathway of tumor cells and enhance¹³ the sensitivity of radiotherapy through the regulation of microRNA-329-3p /NEK2 axis¹⁴. A new circRNA, circABCB10, has been extensively studied in var-

Introduction

Lung cancer (LCa) as one of the most common tumors ranks the third in the world, among which

ious human tumors, including pituitary tumor¹⁵, liver cancer¹⁶ and ovarian cancer¹⁷. CircABC10 is considered to be a key oncogene in tumors progression and is involved in the regulation of a large number of miRNAs with tumor suppressive effects. However, no study has revealed its specific effect and detailed mechanism in LCa.

In this study, we tested the circABC10 expression in LCa tissues and explored the impact of circABC10 on LCa cell functions. We aim to look for target genes of circABC10 related to LCa, and to study their biological functions and their correlation with the prognosis of LCa patients. We characterize a novel axis involving circABC10 and microRNA-217 that governs the progression of LCa, thus provide a new molecular target for diagnosis and treatment of LCa.

Patients and Methods

Patient and Specimens

From June 2017 to March 2019, with the written consent of Shengjing Hospital of China Medical University, 23 matched NSCLC tumor specimens and corresponding adjacent non-cancer tissues were obtained. Fresh specimens were placed in liquid nitrogen immediately after excision and stored at 80°C. None of the patients received chemotherapy or radiotherapy before surgery. The plan was approved by the Ethics Committee of Shengjing Hospital of China Medical University. Tumor pathological classification and staging standards are implemented in accordance with the staging standards of the Union for International Cancer Control (UICC). Inclusion criteria: patients with no severe diseases in other organs, those undergoing no post-operative radiotherapy and those with normal lung function before operation. Exclusion criteria: patients with distant metastasis or metastasis of tumors, those complicated with other malignancies, those with mental disease, those complicated with myocardial infarction, heart failure or other chronic diseases, those with abnormal lung function prior to operation, or those previously exposed to radioactive rays.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted from frozen tissues or cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and then reverse transcribed into cDNA. qPCR was performed on a TP800 real-time PCR instrument (TaKaRa, Kusatsu, Otsu,

Japan), with a two-step standard PCR amplification procedure: the first step (pre-denaturation) 95°C, 30 seconds, 1 cycle; the second step (PCR reaction), 95°C reaction for 5 seconds, 60°C reaction for 30 seconds, 72°C reaction for 30 seconds, with a total of 40 cycles. Primer sequences used in qPCR detection: circ-ABC10: forward 5'-CTAAGGAGTCACAGGAAGACATC-3'; Reverse: 5'-GTAGAATCTCTCAGACTCAAGGTTG-3'; miR-217: forward: 5'-TACTCAACTCACTACTGCATCAGGA-3', reverse: 5'-TATGTTGTTCTGCTCTCTGTGTC-3'; U6: forward: 5'-AGCCCGCACTCAGAACATC-3', reverse: 5'-GCCACCAAGACAATCATCC-3'; glyceraldehyde 3-phosphate dehydrogenase (GAPDH): forward: 5'-GGGAGCCAAAAGGGTCAT-3', reverse: 5'-GAGTCCTTCCACGATACCAA-3'.

Cell Culture

Human lung bronchial epithelial cells (BE-AS-2B) (as a control) and NSCLC cells (SPC-A1, A549, HCC827, H1299) provided by the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) were cultured in 1640 medium (Youkang, Beijing, China) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Hunan, China) at 37°C with 5% CO₂.

Cell Transfection

Both small interfering RNA (si-circABC10) and small interfering RNA (si-control) were provided by Invitrogen (Carlsbad, CA, USA). miR-149 mimics and miR-149 inhibitors were synthesized from RiboBio (Guangzhou, Guangdong, China). The transfection was implemented by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).

Cell Counting Kit-8 (CCK-8) Test

CCK-8 assay (Dojindo Molecular Technologies, Kumamoto, Japan) was conducted to evaluate cell proliferation based on manufacturer's instructions.

5-Ethynyl-2'-Deoxyuridine (EdU) Assay

Cell proliferation was measured using EdU kit (Tenghui, Jinan, China) according to the instructions.

Plate Cloning Experiment

After continuous culture at 37°C for 14 days, cells were stained with crystal violet, and colonies were counted in each dish to estimate the cloning efficiency between different groups. Visible colo-

nies formed by more than 50 cells under the light microscope were included in the statistics.

Transwell Assay

The transwell chamber (8- μ m pore membrane filter) was purchased from Corning Corporation (Corning, NY, USA) and used to determine the cell migration ability. Cells were prepared into cell suspensions and seeded in upper chamber (50,000 cells/well) supplemented with serum-free medium, and then 10% FBS medium was added to the lower compartment.

Cell Wound Healing Assay

The cell monolayer membrane was scratched with a 200 μ L pipette tip after cells were fully adhered. The healing distance of the injured area at 48 hours was normalized by 0 hours as the control variable and was expressed as relative mobility (%).

Dual-Luciferase Assay

Promega luciferase detection kit (Promega, Madison, WI, USA) was used to measure luciferase activity according to the kit instructions. Wild type (WT) or mutant (MUT) predicted microRNA-217 binding sites of circABC10 were cloned into pGL3 vector (circABC10 wt, circABC10 mut) respectively. These structures were cloned and synthesized by China Ribobio (Guangzhou, China).

Statistical Analysis

GraphPad Prism v7.0 software (La Jolla, CA, USA) was used for data analysis, and the data were expressed as $x \pm$ SD (standard deviation).

The *t*-test was used to evaluate the significance between the two groups. The statistical significance was set as $p < 0.05$.

Results

CircABC10 Is Abnormally Highly Expressed In LCa

We performed real-time quantitative PCR analysis and found that circABC10 expression in LCa tissue samples or LCa cell lines was remarkably higher than that in normal ones (Figure 1A, 1B). According to the follow-up information, we performed a gene-related survival analysis of LCa patients. K-M method survival analysis revealed that the prognosis of LCa patients in circABC10 high expression group was poor in comparison to those in circABC10 low expression group (Figure 1C). The above observations show that circABC10 is remarkably overexpressed in LCa and is closely relevant to the poor prognosis of patients.

CircABC10 Promotes the Proliferation of LCa Cells

To further confirm the effect of circABC10 on the progression of LCa, we transfected si-circABC10 and corresponding negative controls in LCa cell lines and used real-time quantitative PCR to verify the efficiency of transfection. Figure 2A shows that si-circABC10 remarkably down-regulated circABC10 expression in LCa cells. Subsequently, we detected the proliferation of cells by using CCK-8 experiment, EDU assay and cell colony forma-




Figure 1. A, qRT-PCR results show that the expression level of circABC10 in lung cancer tissue is significantly higher than that in normal lung tissue; B, qRT-PCR results show that the expression level of circABC10 in lung cancer cell lines is significantly higher than that in normal lung cell lines; C, Survival analysis shows that the survival prognosis of patients with high expression of circABC10 in lung cancer patients is worse than those with lower expression ** $p < 0.01$, *** $p < 0.001$.




Figure 2. A, Transfection of si-circABC10 significantly down-regulates the expression of circABC10 gene in A549 and H1299 cell lines; B-C, CCK-8 experiment results show that after knocking down circABC10 in lung cancer cells, the proliferation ability of A549 and H1299 cell lines appears to be significantly inhibited; D-E, EdU experiment results show that after knocking down circABC10 in lung cancer cells, the proliferation ability of A549 and H1299 cell lines is significantly inhibited, (magnification: 20 \times). F-G, Cell plate cloning experiment results show that after knocking down circABC10 in lung cancer cells, the proliferation ability of A549 and H1299 cell lines is significantly inhibited, (magnification: 20 \times). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

tion assay. As a result, CCK8 results revealed that the cell proliferative ability was inhibited after transfection with si-circABC10 (Figure 2B-2C). Figure 2D and 2E indicate that si-circABC10 significant attenuated the growth activity of LCa cells; consistently, cell plate cloning experiment also revealed a reduction in cell colony formation capacity after knockdown of si-circABC10 (Figure 2F, 2G). Taken together, the above results detect that circABC10 can enhance the proliferation ability of LCa cells.

CircABC10 Promotes the Migration Ability of LCa Cells

We then explored the effect of circABC10 on LCa cell migration. Transwell test indicated that transfection of si-circABC10 down-regulated the migration ability of LCa cells (Figure 3A-3B);

consistently, the migration distance of LCa cell lines was reduced after transfection of si-circABC10 (Figure 3C-3D). Thus, it can be concluded that circABC10 is capable of enhancing the migratory ability of LCa cells.

CircABC10 Binds to MicroRNA-217 and Downregulates Its Expression In LCa

To explore the mechanism by which circABC10 regulates LCa cell functions, we predicted its downstream potential target genes through bioinformatics analysis and found that the 3'UTR region of circABC10 has a binding site with microRNA-217 (Figure 4A). We found that the expression level of microRNA-217 was up-regulated after knockdown of circABC10 in LCa cells (Figure 4B). Subsequently, we found a negative correlation between circABC10 and mi-

croRNA-217 in 23 cases of LCa tissue samples by using Pearson algorithm analysis (Figure 4C). Meanwhile, Luciferase assay further proved that circABC10 do bind to microRNA-217 in A549 and H1299 cell lines (Figure 4D-4E). These results demonstrate that circABC10 may regulate the expression of microRNA-217 through ceRNA mechanism and thus participate in the development of LCa.

MicroRNA-217 Is a Key Downstream Gene of CircABC10

Functional recovery experiments in cell biology research are often used to verify the critical role of signaling pathways. Therefore, to further understand the regulatory role of microRNA-217 in the circABC10 signaling pathway in LCa, we co-transfected si-circABC10 and microRNA-217 inhibitors in A549 and H1299 cell lines, and then observed the cell proliferation or migration ability. As expected, it was found that transfection of microRNA-217 inhibitor partially restored the inhibited impact of si-circABC10 on proliferation rate (Figure 5A-5B), clonal reproduction activity (Figure 5C-5D), migration activity (Figure 5G-5H) and migration distance of LCa cells (Figure 5I-5J). These observations further confirm that circABC10 may play a role in promoting LCa progression *via* inhibiting microRNA-217 expression.

Discussion

In 2018, there were 20, 93, 876 new cases of LCa and 176,1007 deaths, accounting for 11.6% and 18.4% of all cancers, respectively¹⁸. CircRNAs, highly conserved and widely distributed, play an essential regulatory role in tumors and are considered to have the potential to become important molecular markers for tumor diagnosis and treatment¹⁹. They have been extensively reported to be associated with the progression of LCa, and their dysregulation in tumors is often involved in tumor progression²⁰. Currently, molecular therapy has gradually become the treatment choice for solid tumors, and the discovery of more effective molecular targets has become the focus of tumor research²¹.

A newly discovered circRNA, circABC10, has previously been found to be able to act as an oncogene in a variety of tumors but has not been studied in LCa²². By collecting and measuring circABC10 expression in LCa tissue samples, we found an abnormally high expression of circABC10 in LCa, which can predict poor prognosis of LCa patients. To further investigate the role of circABC10 in LCa, we designed a series of functional experiments *in vitro*. We demonstrate that circABC10 remarkably attenuated the migration and proliferation capacity of LCa cells, indicating that this




Figure 3. A-B, Transwell experimental results show that after knocking down circABC10 in lung cancer cells, the migration ability of A549 and H1299 cell lines is significantly inhibited, (magnification: 20 \times). C-D, Cell wound healing test results show that after knocking down circABC10 in lung cancer cells, the migration ability of A549 and H1299 cell lines is significantly inhibited, (magnification: 20 \times). ** $p < 0.01$.




Figure 4. A, Bioinformatics technology predicts that the 3'UTR region of circABC10 has a binding site with miR-217; B, The results of gene expression interference experiments on lung cancer cells show that circABC10 is negatively correlated with miR-217; C, Pearson algorithm correlation analysis reveals that circABC10 and miR-217 had a negative correlation in 23 cases of lung cancer; D-E, Dual-Luciferase reporter gene experiment show that circABC10 and miR-217 have a binding relationship in lung cancer cells. * $p < 0.05$, ** $p < 0.01$.

circular RNA may serve as a key oncogene in the progression of LCa.

To explore the molecular mechanism of circABC10's role in LCa, we used the circRNA target prediction website to predict possible molecular targets for circABC10 and identified microRNA-217 as a potential downstream target for circABC10. MicroRNA-217 can be engaged in the modulation of tumor development. In particular, microRNA-217 can inhibit the EMT

process in gastric cancer cells by negatively regulating PTPN14²³; it can also suppress the migration capacity and proliferation of HeLa cells *via* regulating the MAPK signaling pathway²⁴. In addition, microRNA-217 has been confirmed to act on Sirt1-mediated progression of osteosarcoma²⁵. In LCa, microRNA-217 has been shown to be an important tumor suppressor, including its involvement in the intracellular EMT transformation process and the sensitivity of tumor




Figure 5. A-F, The results of CCK-8, EDU and plate cloning experiments show that transfection of miR-217 inhibitor can restore the inhibited proliferation activity of A549 and H1299 cells caused by sh-circABC10; G-J, The results of transwell experiment and cell wound healing test show that transfection of miR-217 inhibitor can restore the inhibited migration activity of A549 and H1299 cells caused by sh-circABC10. ** $p < 0.01$, *** $p < 0.001$, # $p < 0.05$, ## $p < 0.01$.

cells to chemotherapy^{26,27}. It was also found that microRNA-217 can mediate the regulatory role of non-coding RNA in LCa, such as participating in the LINC01614/microRNA-217 / FOXP1

signal axis, and acting as a key central regulatory factor²⁸. The present study revealed a negative correlation between circABC10 and microRNA-217, and further showed that circABC10

can bind to microRNA-217 in LCa cells. Consistently, our functional reversal experiment *in vitro* showed that microRNA-217 was closely involved in the effect of circABC10 on the proliferative ability and migration capacity of LCa cells, suggesting that circABC10 may play a carcinogenic role by down-regulating microRNA-217 in LCa cells. The circABC10/microRNA-217 signaling pathway may become a new target for the diagnosis and treatment of LCa. Our study further reveals the role and potential mechanism of circABC10 in LCa and provides new options for accurate molecular targeted therapy of LCa.

Conclusions

In summary, circABC10, abnormally highly expressed in both LCa tissues and cell lines, can lead to tumor malignancy in LCa. microRNA-217 is a key downstream gene that mediates the functional regulation of circABC10 on LCa progression. We proposed, for the first time, that circABC10 may have an important biological role in lung cancer and explored its possible molecular mechanisms. We provide a theoretical basis for the clinical diagnosis and treatment of lung cancer.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) TORRE LA, BRAY F, SIEGEL RL, FERLAY J, LORTET-TIEULENT J, JEMAL A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; 65: 87-108.
- 2) FERLAY J, SOERJOMATARAM I, DIKSHIT R, ESER S, MATHERS C, REBELO M, PARKIN DM, FORMAN D, BRAY F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359-E386.
- 3) KOWAL A, WISNIEWSKI A, KUSNIERCZYK P, JANKOWSKA R. Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer. *Thorac Cancer* 2015; 6: 613-619.
- 4) LEE SH, KIM WS, CHOI YD, SEO JW, HAN JH, KIM MJ, KIM L, LEE GK, LEE CH, OH MH, KIM GY, SUNG SH, LEE KY, CHANG SH, RHO MS, KIM HK, JUNG SH, JANG SJ. Analysis of mutations in epidermal growth factor receptor gene in Korean patients with non-small cell lung cancer: summary of a Nationwide Survey. *J Pathol Transl Med* 2015; 49: 481-488.
- 5) NI R, HUANG Y, WANG J. miR-98 targets ITGB3 to inhibit proliferation, migration, and invasion of non-small-cell lung cancer. *Onco Targets Ther* 2015; 8: 2689-2697.
- 6) BAI H, LEI K, HUANG F, JIANG Z, ZHOU X. Exo-circRNAs: a new paradigm for anticancer therapy. *Mol Cancer* 2019; 18: 56.
- 7) NIGRO JM, CHO KR, FEARON ER, KERN SE, RUPPERT JM, OLIVER JD, KINZLER KW, VOGELSTEIN B. Scrambled exons. *Cell* 1991; 64: 607-613.
- 8) KULCHESKI FR, CHRISTOFF AP, MARGIS R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. *J Biotechnol* 2016; 238: 42-51.
- 9) LI G, YANG H, HAN K, ZHU D, LUN P, ZHAO Y. A novel circular RNA, hsa_circ_0046701, promotes carcinogenesis by increasing the expression of miR-142-3p target ITGB8 in glioma. *Biochem Biophys Res Commun* 2018; 498: 254-261.
- 10) MA X, YANG X, BAO W, LI S, LIANG S, SUN Y, ZHAO Y, WANG J, ZHAO C. Circular RNA circMAN2B2 facilitates lung cancer cell proliferation and invasion via miR-1275/FOXK1 axis. *Biochem Biophys Res Commun* 2018; 498: 1009-1015.
- 11) ANASTASIADOU E, JACOB LS, SLACK FJ. Non-coding RNA networks in cancer. *Nat Rev Cancer* 2018; 18: 5-18.
- 12) SHI H, LI H, ZHEN T, DONG Y, PEI X, ZHANG X. hsa_circ_001653 Implicates in the development of pancreatic ductal adenocarcinoma by regulating microRNA-377-mediated HOXC6 axis. *Mol Ther Nucleic Acids* 2020; 20: 252-264.
- 13) LIU P, ZOU Y, LI X, YANG A, YE F, ZHANG J, WEI W, KONG Y. CircGNB1 facilitates triple-negative breast cancer progression by regulating miR-141-5p-IGF1R axis. *Front Genet* 2020; 11: 193.
- 14) GUAN Y, CAO Z, DU J, LIU T, WANG T. Circular RNA circPITX1 knockdown inhibits glycolysis to enhance radiosensitivity of glioma cells by miR-329-3p/NEK2 axis. *Cancer Cell Int* 2020; 20: 80.
- 15) HAN XT, JIANG JQ, LI MZ, CONG QM. Circular RNA circ-ABC10 promotes the proliferation and invasion of thyroid cancer by targeting KLF6. *Eur Rev Med Pharmacol Sci* 2020; 24: 1271-1277.
- 16) FU Y, CAI L, LEI X, WANG D. Circular RNA ABC10 promotes hepatocellular carcinoma progression by increasing HMG20A expression by sponging miR-670-3p. *Cancer Cell Int* 2019; 19: 338.
- 17) CHEN Y, YE X, XIA X, LIN X. Circular RNA ABC10 correlates with advanced clinicopathological features and unfavorable survival, and promotes cell proliferation while reduces cell apoptosis in epithelial ovarian cancer. *Cancer Biomark* 2019; 26: 151-161.
- 18) BRAY F, FERLAY J, SOERJOMATARAM I, SIEGEL RL, TORRE LA, JEMAL A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394-424.
- 19) CUI C, YANG J, LI X, LIU D, FU L, WANG X. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. *Mol Cancer* 2020; 19: 58.

- 20) DRULA R, BRAICU C, HARANGUS A, NABAVI SM, TRIF M, SLABY O, IONESCU C, IRIMIE A, BERINDAN-NEAGOE I. Critical function of circular RNAs in lung cancer. *Wiley Interdiscip Rev RNA* 2020; e1592.
- 21) ZHANG C, MA L, NIU Y, WANG Z, XU X, LI Y, YU Y. Circular RNA in lung cancer research: biogenesis, functions, and roles. *Int J Biol Sci* 2020; 16: 803-814.
- 22) HAN XT, JIANG JQ, LI MZ, CONG QM. Circular RNA circ-ABC10 promotes the proliferation and invasion of thyroid cancer by targeting KLF6. *Eur Rev Med Pharmacol Sci* 2020; 24: 1271-1277.
- 23) CHEN G, YANG Z, FENG M, WANG Z. microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer. *Biosci Rep* 2020; 40: BSR20193176.
- 24) ZHU L, YANG S, WANG J. miR-217 inhibits the migration and invasion of HeLa cells through modulating MAPK1. *Int J Mol Med* 2019; 44: 1824-1832.
- 25) HE S, WANG Z, TANG H, DONG J, QU Y, LV J. MiR-217 inhibits proliferation, migration, and invasion by targeting SIRT1 in osteosarcoma. *Cancer Biother Radiopharm* 2019; 34: 264-270.
- 26) GUO J, FENG Z, HUANG Z, WANG H, LU W. MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. *Mol Cells* 2014; 37: 664-671.
- 27) LU L, LUO F, LIU Y, LIU X, SHI L, LU X, LIU Q. Post-transcriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract. *Toxicol Appl Pharmacol* 2015; 289: 276-285.
- 28) LIU AN, QU HJ, YU CY, SUN P. Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by up-regulating miR-217 and down-regulating FOXP1. *J Cell Mol Med* 2018; 22: 4034-4044.